PIPE • Life Science

Aisling Capital Invests In Eidos Therapeutics

On January 1, 2018, private equity firm Aisling Capital invested in life science company Eidos Therapeutics

Investment Context
  • This is Aisling Capital’s 36th transaction in the Life Science sector.
  • This is Aisling Capital’s 44th transaction in the United States.
  • This is Aisling Capital’s 13th transaction in California.
Investment Fate
  • Eidos Therapeutics was sold to a publicly-traded strategic buyer in 2020.

Explore All 41 PIPE Life Science Deals - Search the Database Free


Investment Summary

Date January 1, 2018
Target Eidos Therapeutics
Sector Life Science
Investor(s) Aisling Capital
Deal Type PIPE

Target Company

Eidos Therapeutics

San Francisco, California, United States
Eidos Therapeutics is a biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart. Eidos Therapeutics was founded in 2013 and is headquartered in San Francisco, California.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.


Deal Context for Investor #
Overall 47 of 56
Sector: Life Science 36 of 42
Type: PIPE 10 of 12
State: California 13 of 15
Country: United States 44 of 52
Year: 2018 7 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-01 Spyre Therapeutics

Waltham, Massachusetts, United States

Spyre Therapeutics is a biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. Spyre Therapeutics was incorporated in 2013 and is based in Waltham, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-15 Arcus Biosciences

Hayward, California, United States

Arcus Biosciences is a biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways. Arcus Biosciences was founded in 2015 and is based in Hayward, California.

Sell -